A Preliminary Study for Evaluating the Dose-Dependent Effect of d-Allulose for Fat Mass Reduction in Adult Humans: A Randomized, Double-Blind, Placebo-Controlled Trial.

Abstract

d-allulose is a rare sugar with zero energy that can be consumed by obese/overweight individuals. Many studies have suggested that zero-calorie d-allulose has beneficial effects on obesity-related metabolism in mouse models, but only a few studies have been performed on human subjects. Therefore, we performed a preliminary study with 121 Korean subjects (aged 20-40 years, body mass index ≥ 23 kg/m²). A randomized controlled trial involving placebo control (sucralose, 0.012 g × 2 times/day), low d-allulose (d-allulose, 4 g × 2 times/day), and high d-allulose (d-allulose, 7 g × 2 times/day) groups was designed. Parameters for body composition, nutrient intake, computed tomography (CT) scan, and plasma lipid profiles were assessed. Body fat percentage and body fat mass were significantly decreased following d-allulose supplementation. The high d-allulose group revealed a significant decrease in not only body mass index (BMI), but also total abdominal and subcutaneous fat areas measured by CT scans compared to the placebo group. There were no significant differences in nutrient intake, plasma lipid profiles, markers of liver and kidney function, and major inflammation markers among groups. These results provide useful information on the dose-dependent effect of d-allulose for overweight/obese adult humans. Based on these results, the efficacy of d-allulose for body fat reduction needs to be validated using dual energy X-ray absorption.

• Authors: Youngji Han, Eun-Young Kwon, Mi Kyeong Yu, Seon Jeong Lee, Hye-Jin Kim, Seong-Bo Kim, Yang Hee Kim, Myung-Sook Choi
• Journal: Nutrients (Nutrients) Vol. 10 Issue 2 (Jan 31 2018) ISSN: 2072-6643 [Electronic] Switzerland
• PMID: 29385054 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Obesity Agents
• Biomarkers
• Blood Glucose
• Inflammation Mediators
• Lipids
• Sweetening Agents
• psicose
• Fructose

Topics

• Abdominal Fat (diagnostic imaging, drug effects, physiopathology)
• Adiposity (drug effects)
• Adult
• Anti-Obesity Agents (administration & dosage, adverse effects)
• Biomarkers (blood)
• Blood Glucose (metabolism)
• Body Mass Index
• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Fructose (administration & dosage, adverse effects)
• Humans
• Inflammation Mediators (blood)
• Lipids (blood)
• Male
• Obesity (blood, diagnosis, drug therapy, physiopathology)
• Preliminary Data
• Republic of Korea
• Subcutaneous Fat (diagnostic imaging, drug effects, physiopathology)
• Sweetening Agents (administration & dosage, adverse effects)
• Time Factors
• Tomography, X-Ray Computed
• Treatment Outcome
• Weight Loss (drug effects)
• Young Adult